Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 5.3% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (AMLX) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and endocrine conditions. The stock had a strong bullish movement today amidst various developments and news in the market.

Why is Amylyx Pharmaceuticals going up?

AMLX stock is up 5.3% on Apr 14, 2026 15:06

• The bullish movement in AMLX stock could be attributed to the selection of AMX0318 as a new development candidate, indicating progress in the company's pipeline for treating neurodegenerative diseases.
• The upcoming presentation at the 25th Annual Needham Virtual Healthcare Conference might have generated positive investor sentiment, as it provides a platform for the company to showcase its innovative therapies and potential market opportunities.
• Despite the investigation into potential breaches of fiduciary duties by insiders, investors seem optimistic about the company's future prospects, possibly due to the focus on addressing diseases with high unmet needs and the positive market analysis reports.
• Overall, the combination of positive corporate developments, upcoming conference presentation, and market analysis highlighting growth potential could have fueled the bullish momentum in AMLX stock today.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

AMLX SEC Filings - Amylyx Pharmaceuticals 10-K, 10-Q, 8-K Forms

This page provides access to Amylyx Pharmaceuticals' (AMLX) SEC filings, including 10-K, 10-Q, and 8-K forms, crucial for investors monitoring the clinical-stage biopharmaceutical company. Recent filings detail insider trading activities, such as stock sales for tax obligations and gifts, as well as significant corporate developments like the selection of AMX0318 as a new development candidate and quarterly financial results. Stock Titan enhances these reports with AI-powered summaries, sentiment analysis, and impact scoring to help users quickly grasp key information.

https://www.stocktitan.net/sec-filings/AMLX/page-5.html

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. Long-term shareholders are encouraged to contact the firm to discuss potential legal actions, such as seeking corporate governance reforms or the return of funds to the company. The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees.

https://www.prnewswire.com/news-releases/did-amylyx-pharmaceuticals-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302738798.html

Amylyx Pharmaceuticals (Nasdaq:AMLX) - Stock Analysis

This report provides a stock analysis for Amylyx Pharmaceuticals (Nasdaq:AMLX), detailing its market capitalization, current share price, analyst consensus target, and valuation. It highlights the company's focus on neurodegenerative diseases and endocrine conditions, outlining key risks such as unprofitability and insider selling, alongside recent news and performance metrics. The analysis also includes community fair value estimates and comparisons with competitors.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals, Inc. announced that its management will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 8:45 a.m. ET. A live webcast of the presentation will be available on the company's investor relations website and for replay for 90 days. The company is focused on developing investigational therapies for endocrine and neurodegenerative diseases.

https://www.businesswire.com/news/home/20260408589311/en/Amylyx-Pharmaceuticals-to-Present-at-the-25th-Annual-Needham-Virtual-Healthcare-Conference

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) announced that its management will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 8:45 a.m. ET. A live webcast and replay of the presentation will be available on the Investor section of the Company's website. The company aims to treat diseases with high unmet needs, focusing on four investigational therapies for endocrine and neurodegenerative conditions.

https://www.biospace.com/press-releases/amylyx-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference

Trending Today

Live Nation Entertainment Inc. ($LYV) Stock Forecast: Down 3.6% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.4% Today

Tesla Inc. ($TSLA) Stock Forecast: Up 7.4% Today

V.F. Corporation ($VFC) Stock Forecast: Up 5.0% Today

DocuSign Inc. ($DOCU) Stock Forecast: Up 5.0% Today

Fidelity National Information Services Inc. ($FIS) Stock Forecast: Up 5.1% Today

Salesforce.com Inc ($CRM) Stock Forecast: Up 5.2% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 7.5% Today

Lyft Inc. ($LYFT) Stock Forecast: Up 7.0% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Up 5.2% Today

Amylyx Pharmaceuticals Price History

12.02.2026 - AMLX Stock was down 6.5%

• The decline in AMLX stock could be connected to investors potentially feeling unimpressed by the disclosures made at a recent conference concerning the avexitide program and the company's overall pipeline expansion.
• Despite the encouraging news of the Phase 3 trial nearing completion and the forthcoming Q3 data release, market expectations may have been higher for significant advancements or milestones.
• The absence of immediate positive triggers or groundbreaking updates might have prompted traders to take profits, as they may have been anticipating a more notable market response to the company's advancements.
• Investors may be taking a profit-making strategy following the conference updates, leading to a temporary downturn in the stock price.

07.03.2026 - AMLX Stock was up 5.0%

• AMLX shares surged by 6.66% on April 6, driven by positive investor sentiment and analyst recommendations pointing towards a potential upside.
• The 7.8% drop following the earnings report showing $0 revenue and concerns over stock dilution from a shelf filing led to a brief decline in the stock price.
• The completion of enrollment and dosing for the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia is a crucial milestone for AMLX, with the outcome expected to shape the company's future revenue prospects and investment narrative.
• Overall, the bullish movement today can be attributed to a mix of positive analyst outlook, milestone achievements in clinical trials, and short-term market reactions to earnings and dilution concerns.

10.02.2026 - AMLX Stock was up 7.7%

• The uptrend in AMLX stock today is linked to the favorable Q4 2025 earnings release that exceeded EPS projections and highlighted significant advancements in the company's pipeline.
• The Co-CEOs' sale of shares to address tax obligations, though initially raising questions, was clarified as obligatory transactions tied to RSU vesting, demonstrating confidence in the company's future outlook.
• Amylyx Pharmaceuticals' reduced net losses and the initiation of new shelf registrations have bolstered the company's financial flexibility, despite the potential for shareholder dilution, positively shaping the stock's investment story.

30.02.2026 - AMLX Stock was down 5.5%

• The bearish movement in AMLX's stock price today can be attributed to a realignment of holdings by a major investment firm, resulting in the firm reporting 0% beneficial ownership of AMLX common stock. This change may have caused uncertainty among investors, leading to a sell-off of the stock.
• Despite analysts on Wall Street maintaining a bullish sentiment on AMLX and reiterating Buy ratings with optimistic price targets, the sudden change in the investment firm's ownership status likely overshadowed these positive recommendations.
• Additionally, the discontinuation of the ORION program for AMX0035, as highlighted in recent SEC filings, could have raised concerns among investors about the company's future pipeline and potential revenue streams, contributing to the bearish market movement.

04.02.2026 - AMLX Stock was up 5.5%

• AMLX reported significantly reduced losses in 2025, with a pivot towards advancing their avexitide program for post-bariatric hypoglycemia (PBH) showing promising results.
• The completion of recruitment for the pivotal Phase 3 LUCIDITY trial and the selection of new development candidates indicate positive progress in their pipeline, boosting investor confidence.
• Despite an insider, Joshua B. Cohen, planning to sell shares, the overall positive financial results and strategic advancements seem to have outweighed any potential concerns, driving the bullish market movement for AMLX today.

25.02.2026 - AMLX Stock was up 5.4%

• An investment firm maintains a "Buy" rating for AMLX with a high price target, suggesting a notable potential for growth and enhancing investor confidence.
• The conclusion of enrollment in the crucial Phase 3 LUCIDITY clinical trial for avexitide in post-bariatric hypoglycemia (PBH) demonstrates advancement in a promising treatment, garnering positive attention in the market.
• Amylyx's updated corporate presentation outlining Phase 3 trial progress and strong financial standing, with funds available until 2028, has further encouraged investors.
• The successful completion of patient enrollment in the Phase 3 LUCIDITY trial, alongside positive updates on other research endeavors and a solid financial position, has solidified the market's positive outlook on Amylyx Pharmaceuticals.

06.03.2026 - AMLX Stock was up 5.1%

• AMLX experienced a notable 3.52% increase in share price on April 2nd, despite reporting $0 revenue in its recent earnings.
• The positive market response could be linked to the successful enrollment and dosing completion of its pivotal Phase 3 LUCIDITY trial, marking a significant achievement for the company.
• Investor confidence in the potential success of avexitide for post-bariatric hypoglycemia, demonstrated by the trial enrollment completion, likely influenced the bullish movement.
• Concerns about stock dilution after the shelf filing appear to have been outweighed by favorable developments in the company's clinical trials, prompting the upward trend in the stock price.

05.02.2026 - AMLX Stock was down 5.9%

• The bearish movement in AMLX today may have been influenced by the Co-CEOs selling shares to cover tax obligations related to the vesting of restricted stock units, sparking concerns about leadership confidence.
• Despite surpassing EPS expectations and showcasing progress in the pipeline with positive Q4 and full-year 2025 earnings, the impact of Co-CEOs' share sales may have outweighed the optimistic results.
• An adverse reaction from investors towards insider selling, despite the company's robust financial standing, ample cash reserves, and advancements in its drug programs.
• The market's response could also be attributed to short-term profit-taking by investors post-recent positive developments, leading to a temporary decline in the stock price.

24.02.2026 - AMLX Stock was down 6.1%

• The completion of enrollment in the pivotal Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia (PBH) did not seem to positively impact AMLX's stock performance.
• Despite the positive developments in the clinical trials and the strong cash position of $317 million providing a financial runway into 2028, investors may have had concerns about the company's overall financial performance.
• The market reaction could be attributed to profit-taking by investors who were expecting a more immediate positive impact on the stock price following the enrollment completion and positive trial updates.
• It's possible that the market sentiment was influenced by external factors or broader industry trends affecting biopharmaceutical companies rather than specific news related to Amylyx Pharmaceuticals.

23.02.2026 - AMLX Stock was up 1.6%

• A surge in the price target and a "buy" rating by Guggenheim analyst, alongside optimistic projections from other analysts, likely boosted the stock's performance.
• Notable investment by Maven Securities LTD in AMLX and increased institutional involvement suggest mounting confidence in the company's future.
• The narrowing of losses, expanded shelf capacity, and strategic focus on advancing its pipeline at Amylyx Pharmaceuticals have likely reassured investors and garnered favorable attention, leading to the upward momentum in the stock price.

14.03.2026 - AMLX Stock was up 5.3%

• The bullish movement in AMLX stock could be attributed to the selection of AMX0318 as a new development candidate, indicating progress in the company's pipeline for treating neurodegenerative diseases.
• The upcoming presentation at the 25th Annual Needham Virtual Healthcare Conference might have generated positive investor sentiment, as it provides a platform for the company to showcase its innovative therapies and potential market opportunities.
• Despite the investigation into potential breaches of fiduciary duties by insiders, investors seem optimistic about the company's future prospects, possibly due to the focus on addressing diseases with high unmet needs and the positive market analysis reports.
• Overall, the combination of positive corporate developments, upcoming conference presentation, and market analysis highlighting growth potential could have fueled the bullish momentum in AMLX stock today.

10.03.2026 - AMLX Stock was down 5.1%

• The bearish movement in AMLX's stock price could be attributed to the ongoing investigation into potential breaches of fiduciary duties by the company's officers and directors. This uncertainty may have led to a lack of investor confidence in the stock.
• Additionally, despite the positive news of AMLX's participation in the 25th Annual Needham Virtual Healthcare Conference to showcase its development candidates, the market may have reacted negatively to the lack of concrete updates or significant announcements during the event.
• The insider trading activities disclosed in the SEC filings, including stock sales for tax obligations and gifts, might have also contributed to the downward pressure on AMLX's stock price as investors may interpret these actions as a lack of long-term confidence in the company's prospects.
• Overall, the combination of legal investigations, lack of significant updates from the healthcare conference, and insider trading activities could have collectively influenced the bearish market movement in AMLX today.